Fig. 2From: Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancerMedian PFS in subjects stratified by the presence/absence of mutations in ctDNA isolated from the a first available post-treatment plasma sample and b last available post-treatment plasma sample. CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; PFS, progression-free survivalBack to article page